Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

Inclusion criteria

• Participant must be at least 18 years of age, at the time of signing the informed consent
• Participants affected by Arrhythmogenic Cardiomyopathy as defined by task force criteria

Exclusion criteria

• Known hypersensitivity to atorvastatin or any of the excipients
• Moderate or severe liver disease
• Muscle disease
• Left ventricular ejection fraction <35%
• Congestive heart failure defined by the New York Heart Association (NYHA) as class III or IV.
• Known cardiomyopathy of other origin: post ischemic, hypertrophic, idiopathic dilated, restrictive; known moderate-to-severe mitral or aortic valvulopathy; pulmonary hypertension; congenital cardiac abnormalities
• Hypercholesterolemic patients that require the use of lipid lowering drugs.
• Heart transplantation
• Estimated life expectancy of less than 2 years
• Any other medical condition that, in the judgment of the investigator, places the patient at risk or makes the patient unreliable or limits the patient's ability to complete the study
• Potent CYP3A4 modifiers such as Erythromycin, Clarithromycin Azole antifungals, Protease inhibitors , Gemfibrozil, Ciclosporin, Danazol
• Fusidic acid (drug for bacterial infections)
• Hepatitis C antivirals as telaprevir, boceprevir, glecaprevir/pibrentasvir and ledipasvir/sofosbuvir combination
• Any other lipid lowering drugs such as Statins, Cholesterol absorption inhibitors, Bile acid sequestrants , PCSK9 inhibitors, Adenosine triphosphate-citrate lyase inhibitors , Fibrates, Omega-3 fatty acid ethyl esters
• Drugs primary indicated as antioxidants
• Enrollment in another clinical trial or past clinical trial in which an investigational drug was administered within 30 days of Visit 1 or within the 5 half-lives of the investigational drug, whichever is longer.
• Pregnant or lactating women
• Women of childbearing age who are not using adequate contraception
• Known dependency on alcohol - drug abuse.
• Contraindications to cardiac magnetic resonance